We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

R3NK:XETRRENK Group AG Analysis

Data as of 2026-09-11 - not real-time

€42.03

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

At €42.02, RENK Group AG shows a bearish moving-average alignment, with shorter averages beneath longer ones. It has lost 11.9% over the past 30 days. Momentum indicators put RSI at 33.0 (approaching oversold) with MACD reading bearish. Recent trading has carved out support near €41.67 and resistance around €52.46.
Valuation screens as overvalued: a P/E of 42.4 sits above the sector average of 27.7. Sell-side targets cluster 51.1% above the current quote. The 1.35% dividend yield looks covered by current payout levels.
Risk comes out at 7 of a possible 10, a elevated reading. With 30-day volatility of 37.0%, a beta of 0.30 and a maximum drawdown of 53.8%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 90 on the fear-greed composite.
The horizons diverge: sell near-term but hold on a long view, at 2/10 conviction over the longer horizon.

Top Market Events

Renk Group AG / Keyword: Mergers and Acquisitions / Purchase of parts of a company Renk Group AG: RENK Enters Into...RENK Group AG's Supervisory Board has extended CEO Dr.RENK Group AG shares on Xetra traded broadly stable on 06/02/2026 as investors look ahead to the Ger

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • Trading below the 200-day average of 51.65
  • MACD momentum is negative

Medium Term

1–3 years
Cautious
Model confidence: 4/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • P/E of 42.4 versus sector average of 27.7
  • Trading below the 200-day average of 51.65

Long Term

> 3 years
Neutral
Model confidence: 2/10

Key Factors

  • P/E of 42.4 versus sector average of 27.7
  • Analyst targets imply +51.1% versus the current price
  • Return on equity of 22.6%

Key Metrics & Analysis

Financial Health

Revenue Growth1.70%
Profit Margin7.17%
P/E Ratio42.4
ROE22.57%
ROA6.29%
Debt/Equity112.55
P/B Ratio9.0
Op. Cash Flow€167.8M
Free Cash Flow€68.1M
Industry P/E27.7

Technical Analysis

TrendBearish
RSI33.0
Support€41.67
Resistance€52.46
MA 20€46.47
MA 50€46.70
MA 200€51.65
MACDBearish
VolumeIncreasing
Fear & Greed Index90.29

Valuation

Fair Value€5.27
Target Price€63.51
Upside/Downside51.11%
GradeOvervalued
TypeBlend
Dividend Yield1.35%

Risk Assessment

Beta0.30
Volatility36.96%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.